Display options
Cite
Miwa S, Yamamoto N, Hayashi K, et al. Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma. Cancers (Basel). 2020;12(7)doi: 10.3390/cancers12071758.
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2020). Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma. Cancers, 12(7), . https://doi.org/10.3390/cancers12071758
Miwa, Shinji, et al. "Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma." Cancers vol. 12,7 (2020). doi: https://doi.org/10.3390/cancers12071758
Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H. Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma. Cancers (Basel). 2020 Jul 02;12(7). doi: 10.3390/cancers12071758. PMID: 32630642; PMCID: PMC7409313.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Jul 02;12(7). doi: 10.3390/cancers12071758.

Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma.

Cancers

Shinji Miwa, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Kentaro Igarashi, Hiroyuki Tsuchiya

Affiliations

  1. Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.

PMID: 32630642 PMCID: PMC7409313 DOI: 10.3390/cancers12071758

Abstract

Rhabdomyosarcoma, the most common soft tissue sarcoma noted in childhood, requires multimodality treatment, including chemotherapy, surgical resection, and/or radiation therapy. The majority of the patients with localized rhabdomyosarcoma can be cured; however, the long-term outcomes in patients with metastatic rhabdomyosarcoma remain poor. The standard chemotherapy regimen for patients with rhabdomyosarcoma is the combination of vincristine, actinomycin, and cyclophosphamide/ifosfamide. In recent clinical trials, modifications of the standard chemotherapy protocol have shown improvements in the outcomes in patients with rhabdomyosarcoma. In various type of malignancies, new treatments, such as molecular targeted drugs and immunotherapies, have shown superior clinical outcomes compared to those of standard treatments. Therefore, it is necessary to assess the benefits of these treatments in patients with rhabdomyosarcoma. Moreover, recent basic and clinical studies on rhabdomyosarcoma have reported promising therapeutic targets and novel therapeutic approaches. This article reviews the recent challenges and advances in the management of rhabdomyosarcoma.

Keywords: chemotherapy; immunotherapy; molecular targeted drug; rhabdomyosarcoma; therapeutic target

References

  1. Nat Rev Drug Discov. 2006 Oct;5(10):835-44 - PubMed
  2. Ann Surg. 1891 Sep;14(3):199-220 - PubMed
  3. Lab Invest. 2007 Apr;87(4):318-25 - PubMed
  4. J Control Release. 2016 Aug 10;235:319-327 - PubMed
  5. Ann Med. 2014 Sep;46(6):372-83 - PubMed
  6. Oncotarget. 2014 Aug 30;5(16):7119-25 - PubMed
  7. J Clin Oncol. 2008 Feb 1;26(4):633-8 - PubMed
  8. Nature. 2013 Jul 11;499(7457):214-218 - PubMed
  9. Mol Ther Oncolytics. 2018 Sep 15;11:52-61 - PubMed
  10. J Clin Oncol. 2007 Oct 20;25(30):4722-9 - PubMed
  11. Radiother Oncol. 2014 Oct;113(1):77-83 - PubMed
  12. Technol Cancer Res Treat. 2012 Jun;11(3):267-78 - PubMed
  13. Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):755-60 - PubMed
  14. J Clin Oncol. 1999 Nov;17(11):3468-75 - PubMed
  15. J Oncol. 2019 Jan 1;2019:7035045 - PubMed
  16. Clin Cancer Res. 2003 Jun;9(6):1941-56 - PubMed
  17. J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):272-6 - PubMed
  18. Pediatr Blood Cancer. 2013 Aug;60(8):1267-73 - PubMed
  19. J Pediatr Hematol Oncol. 2001 May;23(4):215-20 - PubMed
  20. Lancet. 2007 Dec 22;370(9605):2103-11 - PubMed
  21. J Clin Oncol. 2014 Nov 20;32(33):3762-70 - PubMed
  22. PLoS One. 2015 Jul 14;10(7):e0133152 - PubMed
  23. Jpn J Clin Oncol. 2013 Nov;43(11):1073-9 - PubMed
  24. N Engl J Med. 2004 Jun 3;350(23):2335-42 - PubMed
  25. J Clin Oncol. 2011 Mar 1;29(7):917-24 - PubMed
  26. J Clin Oncol. 1999 Dec;17(12):3706-19 - PubMed
  27. Cancers (Basel). 2020 Feb 18;12(2): - PubMed
  28. Cancer Cell. 2013 Dec 9;24(6):710-24 - PubMed
  29. J Clin Oncol. 2010 Sep 20;28(27):4228-32 - PubMed
  30. Cancer. 1988 Jan 15;61(2):209-20 - PubMed
  31. Oncogene. 2001 Sep 10;20(40):5736-46 - PubMed
  32. Cancer Biol Ther. 2002 Mar-Apr;1(2):97-104 - PubMed
  33. Cancer Res. 2006 Jan 1;66(1):24-8 - PubMed
  34. Cancer Res. 2002 Aug 15;62(16):4704-10 - PubMed
  35. Nat Rev Cancer. 2015 Aug;15(8):451-2 - PubMed
  36. Pediatr Blood Cancer. 2012 Jul 15;59(1):5-10 - PubMed
  37. Lancet Oncol. 2020 Apr;21(4):541-550 - PubMed
  38. Onco Targets Ther. 2008 Nov 01;1:67-78 - PubMed
  39. J Clin Oncol. 2016 Jan 10;34(2):117-22 - PubMed
  40. Lancet Oncol. 2019 Nov;20(11):1566-1575 - PubMed
  41. Pediatr Blood Cancer. 2015 Sep;62(9):1562-6 - PubMed
  42. J Clin Oncol. 2006 Jul 20;24(21):3415-22 - PubMed
  43. Int J Mol Sci. 2017 Aug 07;18(8): - PubMed
  44. Cancer. 2009 Nov 15;115(22):5339-48 - PubMed
  45. J Clin Oncol. 2009 Jul 1;27(19):3126-32 - PubMed
  46. Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6 - PubMed
  47. Cancer. 2017 Sep 1;123(17):3291-3304 - PubMed
  48. Cancer Cell. 2007 Jul;12(1):9-22 - PubMed
  49. J Clin Oncol. 2001 Jun 15;19(12):3091-102 - PubMed
  50. Pediatr Blood Cancer. 2017 Jul;64(7): - PubMed
  51. N Engl J Med. 2018 Apr 05;378(14):1277-1290 - PubMed
  52. Science. 2013 Dec 20;342(6165):1432-3 - PubMed
  53. Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90 - PubMed
  54. Pediatr Blood Cancer. 2013 Jun;60(6):1001-8 - PubMed
  55. Eur J Cancer. 2012 Jan;48(2):253-62 - PubMed
  56. Lancet Oncol. 2018 Aug;19(8):1061-1071 - PubMed
  57. Oncotarget. 2015 May 30;6(15):13133-48 - PubMed
  58. Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1071-6 - PubMed
  59. J Clin Oncol. 2018 Sep 20;36(27):2770-2777 - PubMed
  60. Cancer. 2019 Jan 15;125(2):290-297 - PubMed
  61. Cancer. 2009 Sep 15;115(18):4218-26 - PubMed
  62. J Clin Oncol. 2020 Jan 1;38(1):1-10 - PubMed
  63. Pediatr Blood Cancer. 2015 Mar;62(3):440-4 - PubMed
  64. Immunotherapy. 2017 Dec;9(16):1331-1338 - PubMed
  65. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1764-70 - PubMed
  66. Transl Oncol. 2020 Feb;13(2):393-400 - PubMed
  67. BMC Cancer. 2016 Jul 08;16:434 - PubMed
  68. Cancer Res. 2004 Aug 15;64(16):5539-45 - PubMed
  69. Sci Signal. 2018 Nov 20;11(557): - PubMed
  70. Cancers (Basel). 2020 Jan 16;12(1): - PubMed
  71. Lancet. 2012 May 19;379(9829):1879-86 - PubMed
  72. JCO Precis Oncol. 2017;2017: - PubMed
  73. Arch Pathol Lab Med. 2006 Oct;130(10):1454-65 - PubMed
  74. N Engl J Med. 2012 Mar 8;366(10):925-31 - PubMed
  75. Front Oncol. 2015 Aug 07;5:181 - PubMed
  76. Pediatr Blood Cancer. 2014 Mar;61(3):452-6 - PubMed
  77. Lancet Oncol. 2015 Apr;16(4):406-16 - PubMed
  78. Clin Cancer Res. 2020 Mar 1;26(5):1135-1140 - PubMed
  79. Mol Cell Biol. 2000 Jul;20(14):5019-31 - PubMed
  80. Cancer Immunol Immunother. 2015 Oct;64(10):1251-60 - PubMed
  81. Oncotarget. 2017 Mar 24;8(44):75874-75880 - PubMed
  82. Nat Rev Cancer. 2004 May;4(5):335-48 - PubMed
  83. J Clin Oncol. 2003 Jan 1;21(1):78-84 - PubMed
  84. Clin Cancer Res. 2019 Jul 1;25(13):3753-3758 - PubMed
  85. Semin Oncol. 2009 Dec;36 Suppl 3:S3-S17 - PubMed
  86. Nat Med. 2003 Jun;9(6):669-76 - PubMed
  87. Acta Orthop Scand. 1981 Oct;52(5):469-74 - PubMed
  88. J Clin Oncol. 2004 Dec 1;22(23):4787-94 - PubMed
  89. Cancers (Basel). 2020 Feb 21;12(2): - PubMed
  90. Neoplasia. 2006 May;8(5):394-401 - PubMed
  91. Clin Cancer Res. 2016 Jul 1;22(13):3182-91 - PubMed
  92. Cancers (Basel). 2014 Jan 14;6(1):112-27 - PubMed
  93. J Clin Oncol. 2015 May 20;33(15):1688-96 - PubMed
  94. N Engl J Med. 2015 Jul 9;373(2):123-35 - PubMed
  95. Ann Oncol. 2013 Apr;24(4):1093-8 - PubMed
  96. Cancer Res. 2003 Dec 15;63(24):8912-21 - PubMed
  97. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10170-4 - PubMed
  98. Oncotarget. 2014 Dec 30;5(24):12849-61 - PubMed
  99. Front Oncol. 2019 Dec 20;9:1458 - PubMed
  100. Growth Horm IGF Res. 2001 Oct;11(5):289-97 - PubMed
  101. Clin Cancer Res. 2016 Mar 15;22(6):1364-70 - PubMed
  102. Eur J Cancer. 2018 May;94:156-167 - PubMed
  103. N Engl J Med. 2010 Oct 28;363(18):1693-703 - PubMed
  104. Lancet Oncol. 2015 Mar;16(3):257-65 - PubMed
  105. J Clin Oncol. 2008 May 10;26(14):2384-9 - PubMed
  106. Eur J Cancer. 2012 Mar;48(4):579-85 - PubMed
  107. J Clin Oncol. 1992 Aug;10(8):1310-6 - PubMed
  108. Int J Cancer. 2020 Jan 15;146(2):510-520 - PubMed
  109. Cell Growth Differ. 1990 Jul;1(7):325-31 - PubMed
  110. Pediatr Blood Cancer. 2013 Sep;60(9):1411-7 - PubMed
  111. Cancer Cell. 2011 Jan 18;19(1):58-71 - PubMed
  112. Cancer. 1993 Mar 1;71(5):1904-22 - PubMed
  113. South Asian J Cancer. 2013 Apr;2(2):91-7 - PubMed
  114. Science. 2015 Apr 3;348(6230):56-61 - PubMed

Publication Types